Giant Biogene Holding Co., Ltd. (HKG:2367) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Giant Biogene Holding Co., Ltd. (HKG:2367) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Giant Biogene Holding's (HKG:2367) recent performance, when its stock has declined 8.7% over the past three months. However, stock prices are usually driven by a company's financial performance over the long term, which in this case looks quite promising. Specifically, we decided to study Giant Biogene Holding's ROE in this article.
看着巨人生物控股公司(HKG: 2367)最近的表现,很难感到兴奋,当时该公司的股票在过去三个月中下跌了8.7%。但是,股票价格通常由公司的长期财务业绩驱动,在这种情况下,这看起来很有希望。具体而言,我们决定在本文中研究巨人生物控股公司的投资回报率。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回报率或投资回报率是对公司增值和管理投资者资金的有效性的考验。简而言之,投资回报率显示了每美元从其股东投资中产生的利润。
View our latest analysis for Giant Biogene Holding
查看我们对巨人生物控股公司的最新分析
How Is ROE Calculated?
ROE 是如何计算的?
The formula for return on equity is:
股本回报率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营业务)÷ 股东权益
So, based on the above formula, the ROE for Giant Biogene Holding is:
因此,根据上述公式,Giant Biogene Holdings的投资回报率为:
35% = CN¥1.2b ÷ CN¥3.5b (Based on the trailing twelve months to June 2023).
35% = 1.2亿元人民币 ¥35亿元人民币(基于截至2023年6月的过去十二个月)。
The 'return' is the amount earned after tax over the last twelve months. Another way to think of that is that for every HK$1 worth of equity, the company was able to earn HK$0.35 in profit.
“申报表” 是过去十二个月的税后收入金额。另一种思考方式是,每持有价值1港元的股权,该公司就能赚取0.35港元的利润。
What Is The Relationship Between ROE And Earnings Growth?
投资回报率与收益增长之间有什么关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我们已经确定,投资回报率是衡量公司未来收益的有效盈利指标。然后,我们能够评估公司的收益增长潜力,具体取决于公司对这些利润进行再投资或 “保留” 了多少及其有效性。假设其他条件都一样,与功能不相同的公司相比,具有更高股本回报率和更高利润保留率的公司通常具有更高的增长率。
Giant Biogene Holding's Earnings Growth And 35% ROE
巨人生物基因控股公司的收益增长和35%的投资回报率
To begin with, Giant Biogene Holding has a pretty high ROE which is interesting. Second, a comparison with the average ROE reported by the industry of 8.3% also doesn't go unnoticed by us. This likely paved the way for the modest 11% net income growth seen by Giant Biogene Holding over the past five years.
首先,Giant Biogene Holding的投资回报率相当高,这很有趣。其次,与该行业报告的8.3%的平均投资回报率进行比较也不会被我们忽视。这可能为Giant Biogene Holding在过去五年中实现11%的温和净收入增长铺平了道路。
Next, on comparing with the industry net income growth, we found that Giant Biogene Holding's growth is quite high when compared to the industry average growth of 8.8% in the same period, which is great to see.
接下来,与行业净收入增长相比,我们发现巨人生物控股公司的增长相当高,而同期的行业平均增长率为8.8%,这很高兴看到。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231210/0-ead99012b75ac7ff6dc5444a63e66b7e-0-35fb9d61fde395f57c72a63a2e2dcb91.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. What is 2367 worth today? The intrinsic value infographic in our free research report helps visualize whether 2367 is currently mispriced by the market.
赋予公司价值的基础在很大程度上与其收益增长息息相关。对于投资者来说,重要的是要知道市场是否影响了公司的预期收益增长(或下降)。这样做将帮助他们确定股票的未来是光明还是不祥。今天的2367值多少钱?我们的免费研究报告中的内在价值信息图有助于直观地了解市场目前是否对2367进行了错误的定价。
Is Giant Biogene Holding Using Its Retained Earnings Effectively?
Giant Biogene Holding是否有效地使用其留存收益?
Giant Biogene Holding doesn't pay any dividend, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.
巨头Biogene Holding不支付任何股息,这意味着其所有利润都将再投资于该业务,这解释了该公司的收益增长幅度。
Summary
摘要
On the whole, we feel that Giant Biogene Holding's performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
总体而言,我们认为Giant Biogene Holding的表现相当不错。特别是,我们喜欢该公司对其业务进行大量再投资,而且回报率很高。毫不奇怪,这带来了可观的收益增长。话虽如此,从分析师目前的估计来看,我们发现该公司的收益有望增强。要了解有关公司未来收益增长预测的更多信息,请查看这份关于分析师对公司的预测的免费报告,以了解更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。